contrast-induced acute kidney injury
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate in this trial and sign the informed consent; 2. Aged 18 to 80 years old; 3. Proposed coronary stent implantation; 4.AGEF score>1.16; 5. Not taking Qili Qiangxin Capsules or Chinese patent medicines with similar ingredients in the past month; 6. Those who can wait more than 1 week for elective secondary PCI after selection.
Exclusion criteria
Exclusion criteria: 1. Have a history of allergy to Qili Qiangxin Capsules or similar components of proprietary Chinese medicines; 2. Acute ST-segment elevation myocardial infarction (STEMI); 3. NYHA cardiac function class IV, unstable hemodynamics, unable to lie supine for more than 24 hours; 4. Those who have taken Qili Qiangxin Capsules or Chinese patent medicines with similar ingredients within 14 days before enrollment; 5. CT, MRI angiography and other examinations with contrast agents within 14 days before enrollment; it is expected that imaging examinations with other contrast agents will be required during the study period (except for elective PCI after 1 week, which requires the use of the same contrast agent); 6. Blood pressure lower than 120/80mmHg; 7. Abnormal liver function, ALT > 3 times the upper limit of normal; 8. Thyroid dysfunction; 9. Malignant tumors, inflammatory diseases, autoimmune diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of contrast-induced acute kidney injury; | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Outcome Measures; | — |
Countries
China
Contacts
Department of Cardiology, Zhongda Hospital of Southeast University Medical School